Open AccessInterim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
Author(s) -
Yasutomo Teshima,
Minako Kizaki,
Ryohei Kurihara,
Ryosuke Kano,
Miki Harumiya
Publication year - 2020
Publication title -
international journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.06
H-Index - 62
eISSN - 1437-7772
pISSN - 1341-9625
DOI - 10.1007/s10147-020-01737-3
Subject(s) - medicine , dabrafenib , trametinib , rash , oncology , melanoma , adverse effect , vemurafenib , interim analysis , gastroenterology , surgery , clinical trial , metastatic melanoma , cancer , cancer research , kinase , mapk/erk pathway , biology , microbiology and biotechnology
To investigate the safety and efficacy of dabrafenib and trametinib combination therapy for BRAF V600 mutation-positive unresectable and metastatic melanoma in over 100 Japanese patients of a real-world clinical setting.